Skip to main content
MedPathMedPath Home
Clinical Trials/CTIS2024-511104-16-00
CTIS2024-511104-16-00
Active, not recruiting
Phase 1

Molecular theranostics for metastatic prostate cancer: PSMA, FAPI, or both?

Turku University Hospital0 sites40 target enrollmentFebruary 10, 2024
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsProstate cancerTherapeutic area: Diseases [C] - Male Urogenital Diseases [C12]

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Prostate cancer
Sponsor
Turku University Hospital
Enrollment
40
Status
Active, not recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 10, 2024
End Date
TBD
Last Updated
last year
Study Type
Interventional clinical trial of medicinal product
Sex
Male

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Men with histologically confirmed prostate cancer, Age 50\-85 years at baseline, WHO performance score 0\-2, At least one distant metastasis detected on CT, MRI, bone scintigraphy (BS) or single\-photon emission computed tomography (SPECT) imaging, All previous treatment lines are allowed, Patient signs informed consent form after receiving written information

Exclusion Criteria

  • •Patient is not able to understand the purpose of the study, Medical conditions prohibiting whole\-body PET/CT imaging

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Molecular theranostics for metastatic prostate cancer: PSMA, FAPI, or both?Metastatic prostate cancerTherapeutic area: Diseases [C] - Cancer [C04]
EUCTR2022-003788-13-FIHeikki Minn40
Completed
Phase 1
Radionuclide therapy using Lutetium-177 prostate specific membrane antigen (PSMA): a pilot study in men with castrate-resistant prostate cancer (LuPSMA trial)Prostate CancerCancer - Prostate
ACTRN12615000912583Peter MacCallum Cancer Centre30
Completed
Not Applicable
Prostate Cancer Molecular Medicine: Transition Grant 2015 (ProCaMolMed)
NL-OMON42675Erasmus MC, Universitair Medisch Centrum Rotterdam525
Completed
Not Applicable
Prostate Cancer Molecular MedicineProstate cancerprostate carcinoma1003859710036958
NL-OMON39774Erasmus MC, Universitair Medisch Centrum Rotterdam496
Active, not recruiting
Phase 1
Response evaluation with 68Ga-PSMA PET of metastatic prostate cancer castration resistant patients in treatment with 223RaCl2Patients mCRPC eligible to treatment with 223RaCl2MedDRA version: 21.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10005993Term: Bone metastasesSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.1Level: LLTClassification code 10036223Term: Positron emission tomographySystem Organ Class: 100000004848MedDRA version: 21.1Level: PTClassification code 10062904Term: Hormone-refractory prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2017-001395-38-ITAZIENDA USL DELLA VALLE D'AOSTA50